Результаты поиска

Diagnosis and Management of Chronic Pruritus: An Expert Consensus Review.

The aim of this study is to formulate the best clinical practice in the diagnosis and management of chronic pruritus (CP). We searched PubMed, EMBASE, Scopus, Web of Science, and the WHO's regional databases, for studies on "Diagnosis and management of chronic pruritus" from January 1, 2014, to July 31, 2015. We included programmatic reports and hand-searched references of published reviews and articles. Two independent reviewers screened articles and extracted data. We screened 87 of 95 studies that contained qualitative data. Avoid: Dry climate, heat, alcohol compress, ice packs, frequent ba

Совпадение в полном тексте источника
… therapy for uremic pruritus in hemodialysis patients Am J Kidney Dis 2000 35 827 31 10793015 10.1016/s0272-6386(00)70251-4 58 Murphy M Reaich D Pai P Finn P Carmichael AJ A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch Br J Dermatol 2003 148 314 7 12588385 10.1046/ … PA Scott F Epstein O Burroughs AK Scheuer PJ McIntyre N Thalidomide as therapy for primary biliary cirrhosis: A double-blind placebo controlled pilot study J Hepatol 1994 21 496 9 7814794 10.1016/s0168-8278(94)80092-8 74 Schwörer H Ramadori G Improvement of cholestatic pruritus by ondansetron Lancet …

:: воздействие программы < < Передовая практика > > на пациентов с повторной/отправленной миеломой, принимающих Селинксор.

Передовая практика (БП) в области лечения раковых заболеваний включает в себя многоплановый подход, включающий индивидуальные планы лечения, основанную на фактических данных медицину, оптимальное использование вспомогательных услуг и просвещение пациентов. Мы изучили последствия программы BP для пациентов с реанимацией/отменой множественных миелом (RRMM), получающих селинксор. Особенности программы BP, специфичные для селинксора, инициировали селинксор при дозах ≤80 gg раз в неделю и переднее использование стандартизованных антиметиков. К числу конечных точек исследования относятся время, необ

Совпадение в полном тексте источника
… For each new selinexor-based regimen, the clinical pharmacist submitted a request to the treating physician to also prescribe antiemetic therapies such as ondansetron, olanzapine and/or rolapitant prescriptions if none had been ordered. … Aspects of the program that were customized to selinexor included a recommended starting dose of ≤80 mg once weekly and standardized antiemetics consisting of ondansetron, rolapitant and/or olanzapine. …

Structural basis for Mg²⁺-glycine synergy in the tandem glycine riboswitch revealed by cryo-EM.

Part I of this article discussed the potential functional importance of genetic mutations and alleles of the human cytochrome P450 2D6 (CYP2 … oper dose adjustment may be needed when the CYP2D6 genotype is determined in a patient. Dolasetron, ondansetron and tropisetron, all in part metabolized by CYP2D6, are less effective in UMs than in other patients. Overall, there is a strong gene-concentration relationship only for tropisetron. CYP2D6 genotype screening prior to antiemetic treatment may allow …

Adverse side effects of dexamethasone in surgical patients.

BACKGROUND: In the perioperative period, dexamethasone is widely and effectively used for prophylaxis of postoperative nausea and vomiting ( … c) infection with dexamethasone compared with no treatment, placebo, or active control (ramosetron, ondansetron, or tropisetron) (Peto OR 1.01, 95% confidence interval (CI) 0.80 to 1.27; 4931 participants, 27 studies; I² = 27%; moderate-quality evidence). The effects of dexamethasone on delayed wound healing are unclear because the wide confidence interval in …

Drug therapy for obstructive sleep apnoea in adults.

BACKGROUND: The treatment of choice for moderate to severe obstructive sleep apnoea (OSA) is continuous positive airways pressure (CPAP) via … y progesterone, clonidine, mibefradil, cilazapril, buspirone, aminophylline, theophylline doxapram, ondansetron or sabeluzole. AUTHORS' CONCLUSIONS: There is insufficient evidence to recommend the use of drug therapy in the treatment of OSA. Small studies have reported positive effects of certain agents on short-term outcome. Certain agents have been shown t …

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.

Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia. We reviewed 437 patients with multiple myeloma treated with selinexor and assessed the kinetics of adverse events and impact of supportive care measures. Selinexor reduced both platelets and neutrophils over the first cycle of treatment and reached a nadir between 28 and 42 days.

Совпадение в полном тексте источника
… Supportive care agents per drug class: serotonin (5-HT3) receptor agonist (granisetron, mirtazapine, ondansetron, palonosetron), dopamine (D2/D3) receptor antagonist (alizapride, domperidone, haloperidol, metoclorpramide, prochloroperazine, thiethylperazine maleate, trimethobenzamide), neurokinin 1 ( … Prophylactic use of a 5-HT3 RAs (ondansetron or equivalent) in all patients, was mandated on selinexor trials after phase 1 to reduce N/V. The use of a second antiemetic, such as 2.5–10 mg olanzapine in the evening and/or NK1-RAs should be strongly considered prior to the first day of therapy. …

Adverse side effects of dexamethasone in surgical patients.

BACKGROUND: In the perioperative period, dexamethasone is widely and effectively used for prophylaxis of postoperative nausea and vomiting ( … c) infection with dexamethasone compared with no treatment, placebo, or active control (ramosetron, ondansetron, or tropisetron) (Peto OR 1.01, 95% confidence interval (CI) 0.80 to 1.27; 4603 participants, 26 studies; I² = 32%; moderate-quality evidence). The effects of dexamethasone on delayed wound healing are unclear because the wide confidence interval in …

Hypercalcemia of Malignancy: An Emergency Medicine Simulation.

Hypercalcemia is a poor prognostic factor associated with malignancy. The signs and symptoms of hypercalcemia that the patients present to the emergency department are vague and often overlap with the general symptoms of cancer itself or the adverse effects of the chemotherapy. Given that the development of hypercalcemia of malignancy can present with imminent danger to the patient and is a treatable condition, emergency physicians should know how to recognize and treat it. It also marks a time at which discussions regarding plans of care should be initiated with the patients. In this report,

Совпадение в полном тексте источника
… Allergies | No known allergies Medications | Hydrochlorothiazide, ondansetron, dexamethasone, cyclophosphamide, doxorubicin, 5-Fluorouracil (FAC) Past medical history | Stage 2 breast cancer, unilateral modified radical mastectomy, hypertension, cesarean section, appendectomy Social history | Married … Medications of Your Wife Cyclophosphamide, doxorubicin, 5-Fluorouracil (FAC) - this is the chemotherapy; the last dose was two weeks ago Ondansetron (Zofran) 8 mg twice a day as directed– for prevention of nausea and vomiting related to chemotherapy Dexamethasone 8 mg as directed before chemotherapy …

Impact of perioperative lidocaine infusion and bis monitorization on remifentanil dosage in hypotensive anesthesia.

BACKGROUND: Combination of local and regional anesthetic agents are widely used in emergency and surgical setting and the interaction betwee … VRS was greater than 2, 50 mg dolantine was given IM. For prevention of nausea and vomitting, 8 mg ondansetron was given IV. Perioperative total doses of remifentanil, desflurane (ml) (anesthesia machine records) and lidocaine (mg) were recorded after the surgery. Perioperative hemodynamic parameters (systolic, diastolic, mean blood pressures, heart rates) w …

The effect of oral nutrition supplement (ONS) on the nutritional and clinical status of patients undergoing autologous hematopoietic stem cell transplantation: study protocol for a randomized controlled clinical trial.

IntroductionSeveral side effects within the patients undergoing hematopoietic stem cell transplantation (HSCT), especially ones that influence nutrition intake, can cause weight loss and malnutrition. Based on studies, oral nutritional supplement (ONS) may reinforce their nutrient intake and progress clinical outcomes. The objective of this research is to investigate the effect of oral nutrition supplements on the nutritional and clinical status of patients undergoing autologous hematopoietic stem cell transplantation.MethodsAfter block randomization used the website www.randomization , 38 pat

Совпадение в полном тексте источника
… To manage nausea and vomiting, a combination of 5-HT3 receptor antagonists (e.g., ondansetron) and NK1 receptor antagonists (e.g., aprepitant) is used. Granulocyte colony-stimulating factor (G-CSF) is administered post-transplant to promote neutrophil recovery. … Prevention of CINV in patients with multiple myeloma or lymphoma undergoing hematopoietic stem cell transplantation: NEPA Versus Ondansetron. A Monocentric Real-Life experience. Blood. 2023;142:7067. doi: 10.1182/blood-2023-187545. 11. Wang B, Yan X, Cai J, Wang Y, Liu P. …

Оценка иглоукалывания и аурикулотерапии при борьбе с тошнотой и рвотой, вызванной химиотерапией: экспериментальное исследование.

ЦЕЛЬ: Оценка эффективности иглоукалывания и аурикулотерапии в деле уменьшения тошноты, вызванной химиотерапией, и рвоты у больных раком, по сравнению с антиэметическим протоколом. МЕТОД: Пилотное исследование прагматического two- Клинические испытания с применением огнестрельного оружия: группа иглоукалывания получила системную иглоукалывание, аурикулотерапию и антиеметический протокол; контрольная группа использовала антиеметический протокол. Образец состоял из: 42 больные раком желудочно-кишечной системы или множественной миеломой. Результаты были оценены с помощью инструмента химиотерапии п

Совпадение в полном тексте источника
… Patients in both groups used medication for vomiting: Ondansetron hydrochloride, 22.2% (n = 4) of patients in GACA and 8.3% (n = 2) in CG; Dimenhydrinate, 4.2% (n = 1) of patients in the CG; Metoclopramide hydrochloride, 11.1% (n = 2) of patients in GACA and 8.3% (n = 2) in CG. … Participants in both groups received intravenous ondansetron as the basis of their antiemetic regimen. However, the effectiveness of this protocol was not satisfactory, with no noticeable improvement in the acupuncture group compared to the control group. …

Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis.

BACKGROUND: Most cancer patients suffer from the pain of chemotherapy-induced nausea and vomiting (CINV). This meta-analysis was performed to evaluate the efficacy and safety of a regimen consisting of aprepitant, dexamethasone, and 5-HT3 receptor antagonists in the prevention and treatment of CINV. METHODS: A systematic literature search was conducted across multiple databases, including PubMed, EMbase, Cochrane Library, MEDLINE, CENTRAL, HEED, CNKI, Wanfang, and VIP, to identify randomized controlled trials (RCTs) investigating the use of triple therapy (aprepitant, 5-HT3 receptor antagonis

Совпадение в полном тексте источника
… Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol . 2006 ; 17 : 1000 – 6 . 16524979 10.1093/annonc/mdl019 [42] Stiff PJ Fox-Geiman MP Kiley K . … A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat . 2009 ; 113 : 529 – 35 . 18327706 10.1007/s10549-008-9957-9 [51] Yang J Shen Y . …

Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation.

Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment strategy in patients with a hematological disorder. Chemotherapy-induced nausea and vomiting (CINV) is still an issue in patients who undergo HSCT. While several guidelines for the antiemetic therapy against CINV have been published, there is no detailed information about appropriate antiemetic drugs for each conditioning regimen in HSCT. Various studies reported that the triplet of 5-HT3RA, NK1RA, and dexamethasone appears useful in HSCT. However, each antiemetic has unique adverse effects or interactions with

Совпадение в полном тексте источника
… A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer. 2017;25(2):607–613. doi: 10.1007/s00520-016-3445-2. 73. … Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic …

Meperidine compared to morphine for rigors associated with monoclonal antibody-related infusion reactions.

IntroductionInfusion reactions, characterized by symptoms such as rigors, fever, and hypotension, are common adverse events that occur during monoclonal antibody (MAB) therapy. The treatment of rigors often involves opioids, most commonly meperidine, despite limited evidence supporting use in the setting of MAB infusions. This study aims to compare the efficacy and safety of intravenous (IV) meperidine and morphine is treatment of MAB-related rigors, filling a significant gap in the literature.MethodsThis was a single-center, retrospective cohort study which reviewed patients either inpatient

Совпадение в полном тексте источника
… Also, comparing opioids to other agents that target alternative receptors, such as intravenous ondansetron or clonidine, may also shed light on potential opioid-sparing options for treatment of MAB-related rigors. … Comparison of ondansetron and meperidine for treatment of postoperative shivering: a randomized controlled clinical trial . Iran Red Crescent Med J 2014 ; 16 : e13079 . 10.5812/ircmj.13079 PMC4221999 25389473 8 Pauca AL Savage RT Simpson S , et al. …

AGA Clinical Practice Update on Pregnancy-Related Gastrointestinal and Liver Disease: Expert Review.

DESCRIPTION: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update is to review the availabl … ment consists of symptom control with vitamin B6 and doxylamine, hydration, and adequate nutrition; ondansetron, metoclopramide, promethazine, and intravenous glucocorticoids may be required in moderate to severe cases. BEST PRACTICE ADVICE 5: Constipation in pregnant persons may result from hormonal, medication-related, and physiological changes. Treatment o …

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.

Treatment options are limited for multiple myeloma patients who have developed four/five drug-refractory disease. Selinexor (Sel) and belantamab mafodotin (belamaf) were recently approved by the US FDA for treatment of RRMM. The toxicity profile of these drugs is a concern since these agents are used in patients who have already undergone multiple lines of treatment. In this review, we discuss the toxicity profile and strategies for the management of toxicities of Sel and belamaf for the treatment of RRMM. We conducted a comprehensive literature search on PubMed, Embase, Cochrane, and Clinical

Совпадение в полном тексте источника
… Antiemetic use has been reported in 89–100% of the patients receiving Sel and many patients might need two (14–33%) or three antiemetics (5%). 3 , 5 , 6 For nausea/vomiting, 8 mg of ondansetron or equivalent antiemetics such as prochlorperazine, granisetron can be used before the first dose of Sel, and … then ondansetron 8 mg should be given as needed twice daily or thrice daily at least for 2 days. 5 , 6 Those with persistent nausea despite ondansetron or equivalent can be given olanzapine and neurokinin-1 receptor blockers such as aprepitant and rolapitant. 5 , 22 In STORM trial part 1, eight doses …

Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series.

BACKGROUND Numerous treatment options are available for patients with multiple myeloma (MM). Because of the course of the disease, most patients will experience serial relapse or the MM will become refractory to most of these treatments, leaving patients with few or no treatment options over time. Selinexor, a treatment with a novel mechanism of action, is an oral selective inhibitor of nuclear export (SINE) compound that blocks exportin 1, the major nuclear exporter of tumor suppressor proteins. CASE REPORT In this case series, we report on treatment with the weekly oral administration of sel

Совпадение в полном тексте источника
… Nausea was managed with ondansetron and olanzapine and lasted 3 to 4 days. Thrombocytopenia was managed with eltrombopag (50 mg/day). … The dose of selinexor was reduced to 80 mg in December 2019 because of grade 2 nausea (treated with oral ondansetron and 2.5 to 5 mg/day of oral olanzapine), grade 2 fatigue, and grade 4 thrombocytopenia. …

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection.

Multiple myeloma (MM) is one the most common hematological malignancies, and despite the survival prolongation offered by proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs) and anti-CD38 monoclonal antibodies, the need for novel agents is prominent. Selinexor is a first-in-class, oral, selective inhibitor of exportin-1 (XPO1), a vital protein for the exportation of more than 200 tumor suppressor proteins from the nucleus. Both in solid tumors and hematologic malignancies, selinexor-mediated inhibition of nucleus export seems to effectively lead to cancer cell death. Selinexor in combi

Совпадение в полном тексте источника
… Therefore, it is recommended that all patients receive a 5-HT3 antagonist (ondansetron 8mg po twice daily) before the first dose and the following day of selinexor administration for at least 8 weeks. … Close patient surveillance | Weekly for the first 8 weeks: whole blood count, serum sodium, patient weight Nausea and Vomiting | First 8 weeks: 5-HT3 receptor antagonists (eg ondansetron 8 mg) before and after selinexor and the day after. …

Stimulation of the wrist acupuncture point PC6 for preventing postoperative nausea and vomiting.

BACKGROUND: Postoperative nausea and vomiting (PONV) are common complications following surgery and anaesthesia. Antiemetic drugs are only p … h six different types of antiemetic drugs (metoclopramide, cyclizine, prochlorperazine, droperidol. ondansetron and dexamethasone). There was no difference between PC6 acupoint stimulation and antiemetic drugs in the incidence of nausea (RR 0.91, 95% CI 0.75 to 1.10; 14 trials, 1332 participants), vomiting (RR 0.93, 95% CI 0.74 to 1.17; 19 trials, 1708 partic …

The effectiveness of non-invasive complementary therapies in reducing postoperative nausea and vomiting following abdominal laparoscopic surgery in women: a systematic review.

BACKGROUND: Postoperative nausea and vomiting (PONV) are common adverse events following surgery and anaesthesia. The reported incidence is … tion of IPA is much quicker in achieving a 50% reduction in the level of nausea than the antiemetic ondansetron; however there is no evidence that it reduces the need for rescue antiemetics. The remaining three trials, two investigating oral carbohydrate rich beverage and the other guided imagery and music, did not demonstrate that these interventions were ef …